|
POLR2I expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.43389999873733E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.37679999956397E-07 |
| Normal-vs-Stage2 |
1.598450E-04 |
| Normal-vs-Stage3 |
1.42460000018829E-07 |
| Normal-vs-Stage4 |
2.19459999994953E-06 |
| Stage1-vs-Stage2 |
3.855200E-01 |
| Stage1-vs-Stage3 |
9.045900E-02 |
| Stage1-vs-Stage4 |
2.674800E-01 |
| Stage2-vs-Stage3 |
6.320400E-01 |
| Stage2-vs-Stage4 |
8.918000E-01 |
| Stage3-vs-Stage4 |
6.731200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.50020004488994E-09 |
| Normal-vs-AfricanAmerican |
1.971450E-04 |
| Normal-vs-Asian |
1.199310E-04 |
| Caucasian-vs-AfricanAmerican |
9.433400E-01 |
| Caucasian-vs-Asian |
7.094400E-01 |
| AfricanAmerican-vs-Asian |
8.500200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.95570000194323E-08 |
| Normal-vs-Female |
1.44509999522313E-08 |
| Male-vs-Female |
1.760230E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.37970000002596E-06 |
| Normal-vs-Age(41-60Yrs) |
1.34740000268252E-08 |
| Normal-vs-Age(61-80Yrs) |
7.57629999958986E-07 |
| Normal-vs-Age(81-100Yrs) |
6.993900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.017800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.711600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.328000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.506000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.756200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.172400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.751000E-01 |
| Classical-VS-Follicular |
4.637400E-01 |
| Classical-VS-Other |
6.465000E-01 |
| Classical-VS-Normal |
3.1662999999682E-08 |
| Tall-VS-Follicular |
4.140000E-01 |
| Tall-VS-Other |
4.871000E-01 |
| Tall-VS-Normal |
5.276200E-03 |
| Follicular-VS-Other |
8.332200E-01 |
| Follicular-VS-Normal |
5.37409999945559E-07 |
| Other-VS-Normal |
2.395400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.02559985346329E-10 |
| Normal-vs-N1 |
4.44590000000522E-05 |
| N0-vs-N1 |
7.574800E-01 |
|
|
